ASTRO 2025

Join us at Booth #3306 to connect with our incredible team. We are excited to highlight the presence of key staff members who will be available to answer your questions and share insights throughout the event.

Staff Member	Title/Role / Disease Site	Date	Time Slot
Himanshu Nagar, MD	Associate Attending Physician, GU and Brachytherapy	September 28	10:00 a.m. - 11:00 a.m.
Marisa Kollmeier, MD	Brachytherapy Fellowship Director, GU, GYN, and Brachytherapy	September 28	10:00 a.m. - 11:00 a.m. & 3:00 p.m. - 4:00 p.m.
Chris Dee, MD	Chief Resident	September 28	1:00 p.m. - 2:00 p.m.
Roshal Patel, MD	Chief Resident	September 28	1:00 p.m. - 2:00 p.m.
Suzanne Wolden, MD	Attending Physician, Pediatrics	September 29	10:00 a.m. - 11:00 a.m.
Daniel Gorovets, MD	Program Director for Radiation Oncology, GU and Brachytherapy	September 29	11:00 a.m. - 1:00 p.m. & 4:00 p.m. - 5:00 p.m.
Chris Barker, MD	Associate Attending, Skin	September 29	12:00 p.m. - 1:00 p.m.
Marisa Kollmeier, MD	Brachytherapy Fellowship Director, GU, GYN, and Brachytherapy	September 29	4:00 p.m. - 5:00 p.m.
Alex Goglia, MD, PhD	Holman Pathway Chief Resident	September 29	3:00 p.m. - 4:00 p.m.
Nikhil Mankuzhy, MD	Chief Resident	September 29	3:00 p.m. - 4:00 p.m.
Nancy Lee, MD	Proton Fellowship Program Director, H&N and Proton Therapy	September 30	10:00 a.m. - 11:00 a.m.
Simon Powell, MD, PhD	Chairman, Breast	September 30	1:00 p.m. - 2:00 p.m.
Boris Mueller, MD	Attending Physician, MSK Bergen	September 30	1:00 p.m. - 2:00 p.m.
Daniel Gorovets, MD	Program Director for Radiation Oncology, GU and Brachytherapy	September 30	3:00 p.m. - 4:00 p.m.
Chris Dee, MD	Chief Resident	September 30	4:00 p.m. - 5:00 p.m.

Conference / Presentation Schedule

Date	Time	Resident Name	PGY Level	Title	Oral / Poster	PI
9/28/25	4:45-6:00 p.m.	Nikhil Mankuzhy, MD	5	Durvalumab Concurrent and Following Thoracic Radiotherapy vs. Concurrent Chemoradiotherapy and Consolidation Durvalumab in Locally Advanced Non-Small Cell Lung Cancer: A Propensity Matched Analysis of a Prospective Trial	Poster	Shaverdian
9/28/25	4:45-6:00 p.m.	Kaitlyn Lapen, MD	5	Accelerated Partial Breast Irradiation to 40 Gy in 10 Daily Fractions: Long-Term Results of a Phase II Study	Oral	Braunstein
9/28/25	4:45-6:00 p.m.	Helen Zhang, MD and David Miller, MD	4	Safety and Activity of KRAS G12C Inhibitors Combined with Thoracic Radiation Therapy Poster	Poster	Shaverdian
9/28/25	4:45-6:00 p.m.	Amir Safavi, MD	Former Proton Fellow	Long-Term Efficacy and Quality-of-Life Outcomes Following Substantial De-Escalation of Elective Radiotherapy Dose and Volume in Patients Treated With Definitive Chemoradiotherapy For Human Papillomavirus-Associated Oropharyngeal Cancer Oral	Oral	Lee
9/29/25	8:00AM-9:00AM	Sybil Jones, MD	4	Impact of Pain Management Interventions and Radiation Therapy on Pain Control and Treatment Accuracy in Spine Radiation for Metastasis	Poster	Yerramilli
9/29/25	8:00AM-9:00AM	Christopher Jackson, MD	Former Resident/Incoming Faculty	Re-Irradiation with Three-Fraction Stereotactic Body Radiation Therapy for Spinal Metastases	Poster	Yamada
9/29/25	8:00AM-9:00AM	Christopher Jackson, MD	Former Resident/Incoming Faculty	Outcomes Associated with Proton Spine Stereotactic Body Radiation Therapy	Poster	Yamada
9/29/25	10:45AM-12:00PM	Alexander Goglia, MD, PhD	5	Impact of Radiotherapy Site, Modality, and Dose on Subsequent Clonal Hematopoiesis	Oral	Braunstein
9/29/25	10:45AM—12:00PM	Nikhil Mankuzhy, MD	5	Non-Operative Management of Nasal Cavity Cancers with Definitive Proton Beam Therapy or Intensity Modulated Radiation Therapy for Organ Preservation	Poster	Lee
9/29/25	10:45AM—12:00PM	Kaitlyn Lapen, MD	5	Predictors of Skeletal-Related Events and Quality of Life Dimensions among Patients with High-Risk, Asymptomatic Bone Metastases with or without Early Radiation Therapy: Secondary Analysis of a Multicenter, Randomized Phase II Clinical Trial	Oral	Yerramilli & Gillespie
9/29/25	10:45AM—12:00PM	Chris Dee, MD	5	Global Cancer System Characteristics and Cervical Cancer Outcomes	Poster	Dee
9/29/25	10:45AM—12:00PM	Yingzhi Wu, NP-C	APP	Percutaneous Endoscopic Gastrostomy in Patients with Oropharyngeal Cancer in Single Institution Over 5 years	Poster	Lee
9/29/25	10:45AM-12:00PM	Alok DeShane, MD	4	TP53 Mutations and Outcomes after Radiotherapy in Mantle Cell Lymphoma	Oral	Imber & Yahalom
9/29/25	3:00PM -4:00PM	Alexander Terry,MD, PhD	3	Is Partial Breast Irradiation Effective for Early-Stage Breast Cancer Patients with High-Risk Molecular Recurrence Scores?	Poster	Braunstein
9/29/25	5:00PM-6:00PM	Roshal Patel, MD	5	Clinical and Genomic Predictors of Local Failure in NSCLC Patients Treated with Lung SBRT	Oral	Wu
9/29/25	5:00PM-6:00PM	Chris Dee, MD	5	The Impact of National Cancer Systems on Lung Cancer Mortality	Oral	Iyengar
9/30/25	8:00AM-9:00AM	David Miller, MD	4	Early-Stage Breast Cancer with Low Genomic Risk: Optimizing Adjuvant Therapy	Oral	Braunstein
9/30/25	12:45PM-2:00PM	Ross Weber, MD, PhD	4	Toxicity Assessment of Combined External Beam Radiation with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy	Poster	Imber & Gorovets
9/30/25	12:45PM-2:00PM	Christopher Jackson, MD	Former Resident/Incoming Faculty	Impact of Castrate Sensitivity and Genetic Mutations on Local Control after Spine Stereotactic Body Radiation Therapy for Prostate Cancer Spinal Metastases	Oral	Higginson
9/30/25	12:45PM-2:00PM	Chris Dee, MD	4	Osteoradionecrosis as a Complication Following Intensity-Modulated Radiation Therapy or Proton Therapy in the Treatment of Oropharyngeal Carcinoma	Oral	Lee
9/30/25	2:30PM-3:45PM	Alok DeShane, MD	4	When Less Is More: Reducing the Administration of Inappropriate Radiotherapy to Patients with Very Poor Prognosis	Poster	Xu & Yerramilli
9/30/25	2:30PM-3:45PM	Alexandra Dreyfuss, MD	Former Resident	Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study	Oral	Yahalom, Moskowitz & Moskowitz
9/30/25	2:30PM-3:45PM	Revathi Ravella, MD	3	Clinical Outcomes and Patterns of Failures of Patients with Oligometastatic Anal Squamous Cell Carcinoma Treated with Definitive-Intent Chemoradiation and Metastasis-Directed Therapy	Poster	Roth O’Brien & Romesser
9/30/25	2:30PM-3:45PM	Elisa Liu, MD	3	Extended-Field Definitive Chemoradiation for Patients with Anal Squamous Cell Carcinoma with Nodal Metastatic Disease	Poster	Roth O’Brien & Romesser
9/30/25	4:00PM-5:00PM	Kevin Boehm,MD, PhD	4	Machine Learning Using >300,000 H&E Images Refines Cancer of Unknown Primary Subtyping	Poster	Shah/Schultz/Sanchez-Vega
9/30/25	4:00PM-5:00PM	Kaitlyn Lapen, MD	5	The Influence of Dose on Response Duration of Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides in the Modern Era of TSEBT Dose Reduction	Poster	Imber & Yahalom
9/30/25	4:00PM-5:00PM	Roshal Patel, MD	5	Bridging Radiation Durably Controls Patients with Bulky Tumors Treated with CAR-T Cell Therapy	Poster	Imber & Yahalom
9/30/25	5:15PM-6:15PM	Nikhil Mankuzhy, MD	5	Response Rate and Local Control of Response-Adapted Very Low Dose Radiotherapy (RA-VLDRT) with 4 Gy for Indolent Non-Hodgkin Lymphoma	Oral	Imber & Yahalom
9/30/25	5:15PM-6:15PM	Alexander Goglia, MD, PhD	5	Prospective Phase II Trial of Short Course Androgen Deprivation, Pelvic SBRT, and Brachytherapy Boost for NCCN High-Risk Prostate Cancer with Low-Intermediate Risk Decipher Genomic Score	Oral	Gorovets

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists

We're here for you.

Make an appointment

Speak to a care advisor

We treat every type of cancer, including the most important one: yours.

Partner with us to treat your patient’s cancer.

CALL OUR DEDICATED CLINICIAN ACCESS NUMBER

Our mission: Ending cancer for life.

In the U.S.

Outside of the U.S.

ASTRO 2025

Conference / Presentation Schedule